No patient had a 25% or greater rise in serum creatinine 48 hours after receiving a median 13 mL of contrast for diagnostic coronary angiography, with an additional 13 mL for percutaneous coronary intervention.
Contrast-associated acute kidney injury occurred in 9.5% and 9.1% of patients receiving IV sodium bicarbonate and acetylcysteine, respectively, rates which did not differ significantly from the 8.3% rate among those receiving IV sodium chloride.
In a phase 3 trial, acute kidney injury developed in 13.2% of patients undergoing invasive coronary angiography compared with 5.6% of those undergoing computed tomography angiography.
High-risk patients who did not receive guidelines-recommended prophylactic hydration prior to procedures requiring iodinated contrast media had the same rate of contrast-induced nephropathy (CIN) as patients who received usual care, according to results from the phase 3 AMACING trial published online ahead of print in The Lancet.1 CIN refers to the decline in renal function…
Compared with control treatment, RenalGuard therapy correlated with significantly reduced CI-AKI, as well as a reduced need for renal replacement therapy.